Skip to content

Understanding the nature of day/night clock gene Abnormalities in Cardiovascular Diseases and their effect on potency of Cardiac Medicines

Understanding Circadian Abnormalities in Cardiovascular Diseases and Circadian Regulation of Cardiac Medicines

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/08/057003
Enrollment
300
Registered
2023-08-28
Start date
Unknown
Completion date
Unknown
Last updated
2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I219- Acute myocardial infarction, unspecified

Interventions

None listed

Sponsors

IIT hyderabad
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Adults of either gender ( 40 years older group) suffering from cardiovascular diseases (a narrow age range to avoid age-related circadian variations) 2. Cardiovascular disease diagnosed based on the clinical manifestations and confirmed through an electrocardiogram (ECG) 3. Age and gender (and occupation, if possible) matched healthy participants as control subjects based on medical history, clinical examination, and laboratory investigations 4. Subjects (patients and controls) willing to provide written informed consent and comply with protocol requirements

Exclusion criteria

Exclusion criteria: 1. Subjects reluctant to provide written informed consent or to comply with the study protocol 2. Subjects with any significant medical history (ongoing or in the recent past) 3. Currently diagnosed with a neurological or sleep disorder (narcolepsy, obstructive sleep apnea, restless leg syndrome) and/or being prescribed a non-psychotropic medication that can alter sleep and circadian rhythms (such as cortisone) 4. Subjects with severe anemia (Hb level < 7g/dL) 5. Female patients who are pregnant at the time of enrolment 6. Subjects who are chronic alcoholics or smokers

Design outcomes

Primary

MeasureTime frame
Altered rhythmicity of physiological and biochemical parameters in cardiovascular-diseased (CVD) patients.Timepoint: 3 years 6 months

Secondary

MeasureTime frame
Optimal time of the day for beta-blocker administration in CVD patients.Timepoint: 3 years 6 months

Countries

India

Contacts

Public ContactShreyayukta Chakraborty

Continental Hospital

abhisekh.m@continentalhospitals.com9666121115

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026